TITLE
Unleashing Innovation: The Role of Bispecific Antibodies in Managing Diffuse Large B-Cell Lymphoma


PROVIDERSHIP



This educational activity is provided by Albert Einstein College of Medicine-Montefiore Medical Center and RealCME


ACKNOWLEDGEMENT OF FINANCIAL SUPPORT
Supported by an educational grant from Genmab US, Inc.

Release Date: August 8, 2024

Expiration Date: August 8, 2025

Estimated time to complete this activity: 4 hours, 15 minutes 


STATEMENT OF NEED

Diffuse large B cell lymphoma (DLBCL) is the most common large B cell lymphoma, a subtype of non-Hodgkin lymphoma. Up to two-thirds of patients with DLBCL respond to a regimen of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). The remaining 30-40% of patients will experience primary refractory disease or eventually relapse. Only about half of these patients will qualify for autologous stem cell transplantation (ASCT).

Once patients relapse, the standard of care for fit patients has been salvage therapy with non-cross-resistant combination chemoimmunotherapy regimens followed by high-dose chemotherapy and ASCT as stem cell rescue for patients with chemosensitive disease. As the treatment landscape has expanded for hematologic malignancies, novel options that have been effectively used include chimeric antigen receptor T cell (CAR T) therapies, bispecific antibodies, antibody–drug conjugates as chemotherapy-free single agents or in combination with other novel therapeutics, are being integrated into the management of relapse refractory (R/R) DLBCL.

There is currently no consensus on the standard of care after two prior lines of treatment in patients with DLBCL or how to sequence the multiple options that are available. Treatment decisions depend upon the goals of care and individual patient factors.

This educational curriculum establishes meaningful, small group interactions among clinicians with a range of bispecific and CAR T experience to discuss a range of issues including sequencing in R/R MM DLBCL, expectations about adverse events (e.g., CRS, ICANS, infections) and their management based upon clinical trial and real-world experience, and current and evolving models of care between community practitioners and comprehensive cancer centers.

EDUCATIONAL OBJECTIVES
 

• Apply best practices regarding the use of bispecifics in patients with R/R DLBCL including patient eligibility, treatment selection, and sequencing of bispecifics in relation to CAR T therapies.
• Identify signs and symptoms of toxicities experienced while receiving treatment with bispecific antibodies for R/R DLBCL.
• Integrate protocols to manage CRS and ICANS effectively when managing patients experiencing toxicities of bispecifics for treatment of R/R DLBCL.
• Create working relationships among community providers and those at comprehensive cancer centers in order to expand utilization of bispecifics to all patients who may benefit from therapy.

TARGET AUDIENCE
Hematologist/oncologists including those from community practices, and hematology/oncology nurses, and advanced practice providers involved in the care of patients with Diffuse Large B-Cell Lymphoma (DLBCL).

ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by Albert Einstein College of Medicine-Montefiore Medical Center and RealCME, LLC. Albert Einstein College of Medicine-Montefiore Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


CREDIT DESIGNATION STATEMENT
Albert Einstein College of Medicine-Montefiore Medical Center designates this other activity (blended live and enduring curriculum) for a maximum of 4.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 

Other Credits

American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
 

American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
 

American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 4.25 hours of Category 1 credit for completing this program.

 

American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) Program

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.


DISCLOSURE OF FINANCIAL RELATIONSHIPS
The “Policy on Identification, Mitigation, and Disclosure of Relevant Financial Relationships” of Albert Einstein College of Medicine-Montefiore Medical Center requires that any individual in control of content, including faculty, participating in CME activities disclose to the audience all relevant financial relationships with ineligible companies* in the past 24 months. Any individual in control of content who refuses to disclose, or whose disclosed relationships prove to create a conflict of interest, will be recused.

Individuals with the absence of relevant financial relationships with ineligible companies will be disclosed to the audience.

All financial relationships of individuals in a position to control the content of this CME activity are identified and mitigated prior to the educational activity.

*The ACCME defines an ineligible company as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.


DISCLOSURE OF UNLABELED USE
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a clinician relative to diagnostic and treatment options for a specific patient’s medical condition.


ACCREDITED PROVIDER DISCLOSURE
The planners, and the Albert Einstein College of Medicine-Montefiore Medical Center staff for this educational activity have disclosed no relevant financial relationship(s) with an ACCME-defined ineligible company in the last 24 months.

SUMMARY OF FACULTY DISCLOSURES

The “Policy on Identification, Mitigation and Disclosure of Relevant Financial Relationships” of Albert Einstein College of Medicine-Montefiore Medical Center requires that faculty participating in any CME/CE activity disclose to the audience any relevant relationships with an ineligible company or companies.* Any presenter whose disclosed relationships prove to create a conflict of interest, with regard to his or her contribution to the activity, will not be permitted to present.
 

Albert Einstein College of Medicine-Montefiore Medical Center also requires that faculty participating in any CME/CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device, not yet approved in the United States. All financial relationships listed for individuals have been mitigated.
 

*The ACCME defines an ineligible company as those whose primary business is producing, marketing, selling, re -selling, or distributing healthcare products used by or on patients.

The following individuals have no relevant financial relationships with ACCME-defined ineligible companies during the past 24 months:

FACULTY CO-CHAIRS

Muhamad Alhaj Moustafa, MD, MS
Lymphoma Specialist at Mayo Clinic
Jacksonville, Florida

Allison C. Rosenthal, DO
Assistant Professor, Medicine Medical Director
Adolescent and Young Adult Cancer Program
Mayo Clinic, Phoenix, AZ

William Skinner, MD
Peer Reviewer

METHOD OF PARTICIPATION/INSTRUCTIONS ON HOW TO RECEIVE CREDIT
To obtain credit, a score of 70% or better on the Final Assessment is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this curriculum, answered all test questions, completed the Final Assessment, Post Group Assessment, and evaluation, and have received a digital copy of your credit certificate.

• Baseline/Final Assessments: 30 minutes each for a total of up to 1.00 hour of CME
• Three Self-Study Modules (3): 15 minutes each for a total of up to 0.75 hour of CME
• Two Live Group Discussions (2): 30 minutes each for a total of up to 1.00 hours of CME
• Two Group Challenges (2): 30 minutes each for a total of up to 1.00 hours of CME
• Action Plan development: 30 minutes for a total of 0.50 hours of CME

If you are seeking credit, you must complete the assessment and evaluation at the conclusion of the activity. Your certificate can be printed immediately.


DISCLAIMER
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Albert Einstein College of Medicine-Montefiore Medical Center, RealCME or Sanofi and Regeneron. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


PRIVACY STATEMENT
Albert Einstein College of Medicine-Montefiore Medical Center, Center for Continuing Professional Development (Einstein-Montefiore) protects the privacy of personal and other information regarding participants and education collaborators. Einstein-Montefiore will not release personally identifiable information to a third party without the individual’s consent, except such information as is required for reporting to the ACCME. Einstein-Montefiore maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of information collected from you.


COLLECTION AND USE OF YOUR PERSONAL INFORMATION
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing an activity. Required items include first name, last name, middle initial, degree, email address, address and phone number. These items are necessary. Participants are also required to complete an evaluation of each activity. All evaluative information submitted is collected, retained, and used by Einstein-Montefiore to continuously improve the learning experience. Einstein-Montefiore will not transfer, sell, or share personal information with outside parties or otherwise disclose personal information unless required to in a legal process. Einstein-Montefiore will retain your personal data only for the period necessary to accomplish the stated purposes and to comply with applicable laws.


CONTACT INFORMATION
For questions regarding CME credit, contact Albert Einstein College of Medicine-Montefiore Medical Center at cme@montefiore.org.

For technical questions related to this activity, please contact support@gathered.com.